Everything Genetic in Nantwich appoints new medical director

Everything Genetic Ltd in Nantwich has appointed Dr James Mackay as its UK & International Medical Director.

Dr Mackay is one of the UK’s first accredited Consultant Clinical Genetic Oncologist with a special interest in cancer genetics.

He is an Honorary Senior Lecturer in the Research Department of Oncology, the Cancer Institute, and University College London, and has been involved in clinical academic projects throughout his career.

He established the NHS Cancer Genetics Services in East Anglia at Addenbrooke’s Hospital and North East Thames at Great Ormond Street Hospital.

He left the NHS to establish a private practice in 2006, acting as clinical advisor to several commercial genetic testing companies for more than 25 years.

In his new position, Dr Mackay will provide clinical leadership, strategy, and oversight for the provision of the company’s hereditary genetic cancer and somatic mutation testing services.

His experience and expertise will also be called upon to educate and advise patients with cancer and people with a family history of cancer as part of our pre and post-consultative support package to help them make informed decisions.

Dr Mackay said: “I am delighted to join Everything Genetic at such an exciting time for the company.

“The company is experiencing unprecedented growth, and their passion for making genetic cancer testing available to all is very clear to see and is something that I also believe in strongly.

“I thoroughly believe we have a generational opportunity now to shape how people can better access hereditary genetic cancer testing so that we can detect cancer early, personalise treatment planning, and save lives.”

Everything Genetic CEO and Founder, James Price, added: “We are delighted to have appointed Dr Mackay.

“I have known James for many years, and he brings with him significant experience and expertise.

“His appointment marks a significant milestone for our company, as he will be our first in-house medical director appointment.

“We have great ambitions for our hereditary genetic cancer testing service, having recently brought our BRCAtesting service fully in-house with plans to further add to our service offering by partnering with other laboratories, through to developing our own assays.

“Dr Mackay will have a pivotal role in enabling us to deliver on this vision successfully to the benefit of our clinical partners and the patients they refer.”